PEGCETACOPLAN ( DrugBank: Pegcetacoplan )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	6
62	発作性夜間ヘモグロビン尿症	12
222	一次性ネフローゼ症候群	13

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003797-10-NL (EUCTR)	23/07/2021	09/11/2020	A Study to Evaluate the Safety and Efficacy of Pegcetacoplan in Subjects with ALS	A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: PEGCETACOPLAN	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	228	Phase 2	United States;Czechia;Spain;Ukraine;Ireland;United Kingdom;Italy;France;Czech Republic;Argentina;Bra ...
2	EUCTR2019-003797-10-CZ (EUCTR)	13/05/2021	27/10/2020	A Study to Evaluate the Safety and Efficacy of Pegcetacoplan in Subjects with ALS	A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: PEGCETACOPLAN	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	228	Phase 2	United States;Czechia;Spain;Ukraine;Ireland;United Kingdom;Italy;France;Czech Republic;Argentina;Bra ...
3	EUCTR2019-003797-10-IE (EUCTR)	06/04/2021	03/09/2020	A Study to Evaluate the Safety and Efficacy of Pegcetacoplan in Subjects with ALS	A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: PEGCETACOPLAN	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	228	Phase 2	United States;Czechia;Spain;Ukraine;Ireland;United Kingdom;Italy;France;Czech Republic;Canada;Argent ...
4	EUCTR2019-003797-10-DE (EUCTR)	18/02/2021	12/10/2020	A Study to Evaluate the Safety and Efficacy of Pegcetacoplan in Subjects with ALS	A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: PEGCETACOPLAN	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	228	Phase 2	United States;Czechia;Spain;Ukraine;Ireland;United Kingdom;Italy;France;Czech Republic;Argentina;Bra ...
5	EUCTR2019-003797-10-IT (EUCTR)	03/02/2021	28/07/2021	A Study to Evaluate the Safety and Efficacy of Pegcetacoplan in Subjects with ALS	A Phase 2, randomized, double-blind, placebo-controlled, multicenter studyto evaluate the efficacy a ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: Pegcetacoplam Product Code: [APL-2] Other descriptive name: N/A	APELLIS PHARMACEUTCIALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	228	Phase 2	United States;Czechia;Spain;Ukraine;Ireland;United Kingdom;Italy;France;Czech Republic;Argentina;Bra ...
6	NCT04579666 (ClinicalTrials.gov)	September 30, 2020	22/9/2020	MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplanin Adults With Amyotrophic Lat ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy ...	Amyotrophic Lateral Sclerosis;Motor Neuron Disease	Drug: Pegcetacoplan (APL-2);Other: Placebo	Apellis Pharmaceuticals, Inc.	NULL	Recruiting	18 Years	N/A	All	228	Phase 2	United States;Australia;Belgium;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain; ...

First Previous1Next Last

先頭へ

62. 発作性夜間ヘモグロビン尿症

臨床試験数 : 271 / 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 106

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04729062 (ClinicalTrials.gov)	April 5, 2021	25/1/2021	Pegcetacoplan Early Access Program for PNH	Early Access Program (EAP) For The Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) With Pegce ...	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Drug: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	No longer available	18 Years	N/A	All			United States
2	NCT04901936 (ClinicalTrials.gov)	February 4, 2021	8/3/2021	A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)	An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinestics, and Biologic Act ...	Paroxysmal Nocturnal Hemoglobinuria (PNH);Paroxysmal Hemoglobinuria	Drug: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Recruiting	12 Years	17 Years	All	12	Phase 2	United States
3	EUCTR2019-001106-23-FR (EUCTR)	04/02/2020	15/10/2019	An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Eff ...	An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Eff ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: APL-2 Product Code: APL-2 INN or Proposed INN: pegcetacoplan Other descriptive name: APL- ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	119	Phase 3	France;Canada;Belgium;Malaysia;Poland;Australia;Bulgaria;Germany;Japan;Korea, Republic of;United Kin ...
4	EUCTR2019-001106-23-ES (EUCTR)	22/01/2020	14/01/2020	An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Eff ...	An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Eff ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: APL-2 Product Code: APL-2 INN or Proposed INN: pegcetacoplan Other descriptive name: APL- ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	119	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Serbia;United States;Hong Kong;Spain;Thailand;Russian Federation;United Kingdom;France;Canada;Poland ...
5	EUCTR2019-001106-23-GB (EUCTR)	19/12/2019	30/09/2019	An Open Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long Term Safety and Effic ...	An Open Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long Term Safety and Effic ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: Pegcetacoplan(APL-2) Product Code: Pegcetacoplan(APL-2) INN or Proposed INN: pegcetacopl ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	160	Phase 3	Serbia;United States;Hong Kong;Spain;Thailand;Russian Federation;United Kingdom;France;Canada;Malays ...
6	NCT04085601 (ClinicalTrials.gov)	August 15, 2019	9/9/2019	A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH	A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety ...	Paroxysmal Nocturnal Hemoglobinuria	Drug: APL-2	Apellis Pharmaceuticals, Inc.	NULL	Completed	18 Years	N/A	All	53	Phase 3	Colombia;Hong Kong;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Singapore;Thailand
7	EUCTR2019-001106-23-BG (EUCTR)	09/08/2019	09/05/2019	An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic ...	An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic ...	Paroxysmal Nocturnal Hemoglobinuria MedDRA version: 21.1;Level: LLT;Classification code 10055629;Ter ...	Product Name: pegcetacoplan Product Code: pegcetacoplan INN or Proposed INN: pegcetacoplan Other descri ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	160	Phase 3	Serbia;United States;Hong Kong;Spain;Thailand;Ireland;Russian Federation;United Kingdom;Italy;France ...
8	EUCTR2018-004220-11-PL (EUCTR)	23/07/2019	13/05/2019	A Research Study to Gather Scientific Information About the Efficacy and Safety of the Investigation ...	A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety ...	Paroxysmal Nocturnal Hemoglobinuria (PNH) MedDRA version: 20.1;Level: LLT;Classification code 100556 ...	Product Name: APL-2 Product Code: APL-2 INN or Proposed INN: pegcetacoplan Other descriptive name: APL- ...	Apellis Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	54	Phase 3	Serbia;Philippines;Hungary;Hong Kong;Mexico;Argentina;Thailand;Malaysia;Brazil;Poland;Peru;Colombia
9	EUCTR2017-004268-36-GB (EUCTR)	08/01/2019	21/08/2018	A Research Study to Gather Scientific Information About the Efficacy, Safety, and Tolerability of th ...	A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate th ...	PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-medi ...	Product Name: Pegcetacoplan(APL-2) Product Code: Pegcetacoplan(APL-2) INN or Proposed INN: n/a Other de ...	Apellis Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	United States;Spain;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Australia;Germany; ...
10	NCT03531255 (ClinicalTrials.gov)	August 27, 2018	9/5/2018	Pegcetacoplan Long Term Safety and Efficacy Extension Study	An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Eff ...	PNH	Drug: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	160	Phase 3	United States;Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Ma ...

First Previous1 2Next Last

先頭へ

222. 一次性ネフローゼ症候群

臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-003767-25-ES (EUCTR)	25/02/2022	25/02/2022	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...
2	EUCTR2020-003767-25-NL (EUCTR)	16/02/2022	13/10/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...
3	EUCTR2020-003767-25-PL (EUCTR)	08/02/2022	09/11/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ...	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;Switzerland;United Kingdom;Italy;France;C ...
4	EUCTR2020-002637-15-FR (EUCTR)	09/06/2021	02/02/2021	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETAC ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN); ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	United States;France;Argentina;Spain;Brazil;Austria;Australia;Netherlands;United Kingdom;Switzerland ...
5	EUCTR2020-002637-15-IT (EUCTR)	09/04/2021	04/06/2021	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: [APL-2] INN or Proposed INN: Pegcetacoplan Trade Name: Preven ...	APELLIS PHARMACEUTCIALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;Argentina;Spain;Brazil;Austria;Australia;Netherlands;United Kingdom;Switzerland;Italy;United ...
6	EUCTR2020-002637-15-NL (EUCTR)	29/03/2021	04/01/2021	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETAC ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN); ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;United States;Argentina;Spain;Brazil;Austria;Australia;Netherlands;United Kingdom;Switzerland ...
7	NCT04572854 (ClinicalTrials.gov)	February 23, 2021	29/9/2020	Study Assessing the Safety and Efficacy of Pegcetacoplanin Post-Transplant Recurrence of C3G or IC-M ...	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetac ...	C3G;IC-MPGN;Renal Transplant;Complement 3 Glomerulopathy;Complement 3 Glomerulopathy (C3G);Dense Dep ...	Drug: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Recruiting	18 Years	N/A	All	12	Phase 2	United States
8	EUCTR2020-002637-15-GB (EUCTR)	22/12/2020	23/10/2020	Phase 2, multicenter, open-label, randomized, controlled study is designed to evaluate the safety an ...	AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETAC ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN); ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	United States;France;Argentina;Spain;Brazil;Austria;Australia;Netherlands;Switzerland;Italy;United K ...
9	EUCTR2020-003767-25-DE (EUCTR)		04/10/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan	Apellis Pharmaceuticals, Inc.	NULL	NA			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...
10	EUCTR2020-003767-25-FR (EUCTR)		29/10/2021	A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplanadministered subcutaneously in P ...	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficac ...	complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) ...	Product Name: Pegcetacoplan Product Code: APL-2 INN or Proposed INN: Pegcetacoplan Product Name: Pegcet ...	Apellis Pharmaceuticals, Inc.	NULL	NA			Female: yes Male: yes	100	Phase 3	United States;Czechia;Finland;Spain;Ukraine;Austria;Israel;United Kingdom;Switzerland;Italy;France;C ...

First Previous1 2Next Last

先頭へ